ND Committee Review
Internal Medical Policy Committee 1-22-2020 New Policy
Internal Medical Policy Committee 1-19-2021 Annual review, no clinical content change
Internal Medical Policy Committee 7-22-2021
Updated
NCCN recommendations and diagnosis codes
Internal Medical Policy Committee 7-21-2022 Annual review, no clinical content change
Internal Medical Policy Committee 11-29-2022
- Removed
NCCN recommendations;
and
- Added
this statement 'Panitumumab (Vectibix) may be considered medically necessary for treatment of any of the current category 1 or 2A NCCN recommendations.';
and
- Updated
experimental/investigational statement;
and
- Removed
diagnosis codes C17.0, C17.1, C17.2, C17.8, C17.9, Z85.038 and Z85.068
Internal Medical Policy Committee 11-15-2023
Effective January 01, 2024
- Removed
diagnosis code C18.1
Internal Medical Policy Committee 11-19-2024
Effective December 08, 2024